| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
ML267 targets Sfp phosphopantetheinyl transferases (PPTases), a family of enzymes essential for bacterial secondary metabolism and virulence. It potently inhibits Sfp-PPTase with an IC50 of 0.29 μM. ML267 also inhibits AcpS-PPTase with an IC50 of 8.1 μM. By inhibiting these enzymes, ML267 disrupts the phosphopantetheinylation of carrier proteins, attenuating the production of secondary metabolites and impeding bacterial growth.
|
|---|---|
| ln Vitro |
ML267 is a potent inhibitor of Sfp phosphopantetheinyl transferases (PPTases) with an IC50 of 0.29 μM. It also inhibits AcpS-PPTase with an IC50 of 8.1 μM. ML267 has specific bactericidal (bacteria killing) activity against Gram-positive (Gram+) bacteria. The compound attenuates secondary metabolism and impedes bacterial growth when applied to Bacillus subtilis at sublethal doses.
|
| ln Vivo |
In vivo activity data for ML267 are limited as the compound is primarily a research tool for in vitro studies. As a potent inhibitor of bacterial PPTases, ML267 may have potential for in vivo efficacy in animal models of Gram-positive bacterial infections. However, detailed in vivo efficacy studies have not been extensively reported. The compound could be used in mouse models of bacterial infection to evaluate its therapeutic potential.
|
| Enzyme Assay |
PPTase enzyme activity assays are performed using recombinant Sfp-PPTase or AcpS-PPTase enzymes and appropriate substrates (e.g., acyl carrier protein or peptide substrates). The assay measures the transfer of the phosphopantetheine moiety from coenzyme A to the substrate. ML267 is incubated with the enzyme and substrates in assay buffer for 15-30 minutes. The reaction is stopped and product formation is quantified using fluorescence-based or radiometric methods. IC50 values are calculated from concentration-response curves.
|
| Cell Assay |
Bacterial growth inhibition assays are performed using Gram-positive bacterial strains (e.g., Bacillus subtilis). Bacteria are cultured in appropriate media and treated with varying concentrations of ML267 for 24-48 hours. Bacterial growth is monitored by measuring optical density at 600 nm (OD600) or by colony counting. Minimum inhibitory concentration (MIC) values are determined. The compound's specific bactericidal activity against Gram-positive bacteria is confirmed by comparing activity against Gram-negative strains.
|
| Animal Protocol |
In vivo efficacy of ML267 would typically be evaluated in mouse models of Gram-positive bacterial infection. Infected mice would be treated with ML267 via intraperitoneal or oral administration at various doses. Bacterial burden in tissues or blood would be measured by colony counting. Survival rates would be recorded. However, detailed published in vivo protocols for ML267 are limited as the compound is primarily a research tool for in vitro studies.
|
| ADME/Pharmacokinetics |
ML267 has molecular formula C19H18ClF6N5O3S and molecular weight 545.89. It has CAS number 1542213-67-1. The compound is a solid and should be stored at -20°C for long-term stability. It is soluble in DMSO. The compound is a research-use only reagent for studying bacterial PPTases and secondary metabolism.
|
| Toxicity/Toxicokinetics |
Toxicological data for ML267 are limited as it is a research compound. As a PPTase inhibitor targeting bacterial metabolism, potential toxicities would be related to effects on host enzymes if selectivity is not absolute. The compound should be handled with appropriate laboratory safety precautions. Standard preclinical safety assessments would be required for any therapeutic development.
|
| Additional Infomation |
ML267 is also known as 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide trifluoroacetate. It is a potent inhibitor of Sfp phosphopantetheinyl transferases (PPTases) with IC50 of 0.29 μM. ML267 also inhibits AcpS-PPTase with IC50 of 8.1 μM. The compound has specific bactericidal activity against Gram-positive bacteria. It is a research-use only compound for studying bacterial secondary metabolism.
|
| Molecular Formula |
C19H18CLF6N5O3S
|
|---|---|
| Molecular Weight |
545.886342525482
|
| Exact Mass |
545.072
|
| CAS # |
1542213-67-1
|
| PubChem CID |
60138143
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
35
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=NC=C1)NC(=S)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)Cl.C(=O)(C(F)(F)F)O
|
| InChi Key |
JYBCQVLONAEAQQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H17ClF3N5OS.C2HF3O2/c1-27-12-2-3-22-14(9-12)24-16(28)26-6-4-25(5-7-26)15-13(18)8-11(10-23-15)17(19,20)21;3-2(4,5)1(6)7/h2-3,8-10H,4-7H2,1H3,(H,22,24,28);(H,6,7)
|
| Chemical Name |
4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8319 mL | 9.1594 mL | 18.3187 mL | |
| 5 mM | 0.3664 mL | 1.8319 mL | 3.6637 mL | |
| 10 mM | 0.1832 mL | 0.9159 mL | 1.8319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
